Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

Tranquillo data support ritlecitinib for NSV
27 Oct 2026
bởiAudrey Abella
In two pivotal phase III Tranquillo studies, individuals with nonsegmental vitiligo (NSV) achieved significant and clinically meaningful improvements in facial and total body repigmentation after 52 weeks of treatment with oral ritlecitinib.
27 Oct 2026

CGM initiation reduces hospitalizations for acute diabetes events
26 Oct 2026
bởiAudrey Abella
In an observational study, the rates of hospitalizations for acute diabetes events (ADEs) decreased following the initiation of the FreeStyle Libre (FSL) continuous glucose monitoring (CGM) system in adults with type 2 diabetes (T2D).
26 Oct 2026

Retatrutide poised to be the next weight-loss option for T2D with obesity
24 Oct 2026
bởiElvira Manzano
In the phase III TRIUMP-2 trial, retatrutide improves glycaemic control and reduces body weight in adults with type 2 diabetes (T2D) who are overweight or have obesity, potentially expanding weight-loss options for this population.
24 Oct 2026





